Related Experiment Video

Updated: Nov 23, 2025

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

1.1K

RNA-Binding Motif Protein 38 as a Potential Biomarker and Therapeutic Target in Cancer

Xiaomin She1, Yan Lin1, Rong Liang1

  • 1Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, People's Republic of China.

Oncotargets and Therapy
|December 31, 2020
PubMed

Insights

RNA-binding motif protein 38 (RBM38) regulates gene expression by binding to messenger RNAs (mRNAs). This RNA-binding protein (RBP) influences tumor development and may offer potential in cancer therapy.

Area of Science:

  • Molecular Biology
  • Gene Regulation
  • Cancer Biology

Background:

  • RNA-binding proteins (RBPs) are crucial regulators of RNA metabolism and gene expression.
  • RNA-binding motif protein 38 (RBM38) is an RBP that influences mRNA stability and translation.
  • RBM38 impacts biological processes including cell proliferation, cell cycle arrest, and differentiation.

Purpose of the Study:

  • To review the role of RBM38 in tumor manifestation and development.
  • To highlight RBM38's regulation of tumor-related genes.
  • To explore the potential of RBM38 in cancer therapy.

Main Methods:

  • Literature review of studies on RBM38 and cancer.
  • Analysis of RBM38's interaction with 3' untranslated regions (3' UTRs) of target mRNAs.
  • Examination of RBM38's impact on tumor-related gene expression.

Main Results:

  • RBM38 binds to the 3' UTRs of tumor-related genes (e.g., p53, c-Myc), modulating their mRNA stability and expression.
  • Abnormal RBM38 expression is linked to various malignant tumors and patient prognosis.
  • RBM38 plays a significant role in tumor initiation and progression.

Conclusions:

  • RBM38 is a key regulator of gene expression with implications in cancer.
  • RBM38's involvement in tumor biology suggests its potential as a therapeutic target.
  • Further research into RBM38 could lead to novel cancer treatment strategies.
Keywords:
RBM38malignant tumorsp53 familyposttranscriptional regulation

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.3K
Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

6.9K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.8K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.8K